Acclinate Raises $7M in Series A Funding to Accelerate Health Equity RevolutionBIRMINGHAM, Ala., May 7, 2024-- Acclinate, a trailblazer in mobilizing diverse communities for enhanced health equity, today announced its $7 million Series A financing round. Led by Cencora Ventures, with notable contributions from Labcorp and Latimer Ventures, the funding will enable Acclinate to scale its impact in the clinical trial diversity and health equity landscapes..

2024年5月7日，阿拉巴马州伯明翰，Acclinate在A系列融资中筹集了700万美元，以加速健康公平革命。Acclinate是动员不同社区促进健康公平的先驱，今天宣布了其700万美元的A系列融资回合。在Cencora Ventures的领导下，Labcorp和Latimer Ventures做出了显著贡献，这笔资金将使Acclinate能够扩大其在临床试验多样性和健康权益领域的影响。。

'This investment marks a significant milestone for Acclinate and underscores our commitment to revolutionizing health equity and clinical trial diversity at a larger scale,' expressed Del Smith, CEO and Co-Founder of Acclinate. 'With the backing of prominent healthcare organizations like Cencora and Labcorp, we are poised to accelerate tangible change in the healthcare industry and empower diverse communities to proactively manage their health.'.

Acclinate首席执行官兼联合创始人德尔·史密斯（DelSmith）表示：“这项投资标志着Acclinate的一个重要里程碑，突显了我们致力于在更大范围内彻底改变健康公平和临床试验多样性。”在Cencora和Labcorp等著名医疗保健组织的支持下，我们准备加速医疗保健行业的有形变革，并赋予不同社区积极管理其健康的权力。”。

Acclinate is focused on driving diversity in clinical trials with a unique community engagement platform trusted by top pharmaceutical clients to help make existing trials more inclusive and plan more diverse studies moving forward. Cencora Ventures, formerly known as AB Health Ventures, is the corporate venture fund originally started by AmerisourceBergen prior to becoming Cencora, a leader in global healthcare solutions.

Acclinate专注于通过顶级制药客户信任的独特社区参与平台推动临床试验的多样性，以帮助使现有试验更具包容性，并计划更多样化的研究。Cencora Ventures，以前称为AB Health Ventures，是AmerisourceBergen在成为全球医疗保健解决方案领导者Cencora之前最初成立的企业风险基金。

The fund both invests and provides commercial support to emerging healthcare startup companies and brings unparalleled expertise and resources to this strategic partnership. This funding will help fuel Acclinate' s expansion and enhance its already powerful Enhanced Diversity in Clinical Trials (e-DICT) platform..

该基金为新兴的医疗保健初创公司投资并提供商业支持，并为这一战略伙伴关系带来无与伦比的专业知识和资源。这笔资金将有助于推动Acclinate的扩张，并增强其已经强大的增强临床试验多样性（e-DICT）平台。。

As Acclinate continues to pioneer initiatives aimed at inclusivity and equity in healthcare, this infusion of capital propels its mission forward, bringing us one step closer to a future where healthcare is truly accessible to all.

随着Acclinate继续开创旨在实现医疗保健包容性和公平性的举措，这种资本注入推动了其使命的前进，使我们离人人真正享有医疗保健的未来又近了一步。

About Acclinate

关于Acclinate

Acclinate is a digital health company that leverages a unique combination of sustained community engagement and predictive analytics to improve health equity. Acclinate's community platform helps pharmaceutical companies increase diversity in their clinical trials and other healthcare organizations support inclusivity in their initiatives.

Acclinate是一家数字健康公司，利用持续的社区参与和预测分析的独特组合来改善健康公平。Acclinate的社区平台帮助制药公司增加临床试验的多样性，其他医疗保健组织支持其举措的包容性。

For more information on Acclinate, visit www.acclinate.com..

有关Acclinate的更多信息，请访问www.Acclinate.com。。

About Cencora

关于Cencora

Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions.

Cencora是一家领先的全球制药解决方案组织，致力于改善世界各地人和动物的生活。我们与价值链上的制药创新者合作，以促进和优化治疗的市场准入。护理提供者依靠我们安全可靠地提供药品、保健产品和解决方案。

Our 46,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $250 billion in annual revenue. Learn more at www.cencora.com..

我们的46000多名全球团队成员通过我们的目标为积极的健康结果做出贡献：我们团结一致，共同创造更健康的未来。Cencora在财富500强中排名第11位，在全球财富500强中排名第24位，年收入超过2500亿美元。更多信息，请访问www.cencora.com。。

For media inquiries or additional information, please contact:

有关媒体咨询或其他信息，请联系：

Tiffany Whitlow

蒂芙尼·惠特洛

Cofounder/Chief Development Officer

联合创始人/首席开发官

tiffany@acclinate.com

tiffany@acclinate.com

256-435-2800-office

256-435-2800-办公室

256-322-2387-cell

256-322-2387-单元